Mania: Clinical Trials

45 trials for Mania, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

45 completed. 45 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 345Completed 45
Phase 21Completed 1

Follow Mania: new trials by email Literature Review of Mania trials Research Report on Mania

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BHV-7000 Acute Treatment of Bipolar Mania
BHV-7000, Placebo - Bipolar Disorder
Phase 2 / Phase 3CompletedBiohaven Therapeutics Ltd.2742024-05-282025-12-16
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
Probio-Tec BG-VCap-6.5, Placebo - Mania (Neurotic)
Phase 3CompletedUniversity of Texas Southwestern Medical Center672018-09-062025-12-19
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
Cariprazine, Placebo - Bipolar I Disorder, Mania
Phase 3CompletedAbbVie9012018-06-152023-09-28
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
Brexpiprazole - Bipolar I Disorder, Acute Mania
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.3812017-10-242020-08-17
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
Brexpiprazole, Placebo - Bipolar I Disorder, Manic Episode
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.3332017-09-192020-02-11
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
Brexpiprazole, Placebo - Bipolar I Disorder, Manic Episode
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.3222017-09-142020-02-10
Methylphenidate for the Treatment of Acute Mania
methylphenidate, Placebo - Mania
Phase 3CompletedMichael Kluge422012-03-012016-06-10
Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence
Citicoline, Placebo - Mania, Hypomania
Phase 3CompletedUniversity of Texas Southwestern Medical Center442010-07-012014-08-11
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode
Allopurinol, Placebo - Mania
Phase 3CompletedSheba Medical Center1802010-05-012012-05-08
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
Cariprazine - Bipolar I Disorder
Phase 3CompletedForest Laboratories4032010-02-282019-06-13
Safety and Efficacy of Cariprazine for Bipolar I Disorder
Cariprazine, Placebo - Mania, Bipolar I Disorder
Phase 3CompletedForest Laboratories4972010-02-012017-04-12
Safety and Efficacy of Cariprazine for Mania
Cariprazine, Placebo - Bipolar Disorder, Mania
Phase 3CompletedForest Laboratories3232010-02-012017-04-17
Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes
Phenytoin (brand name Dilantin), Hydrocortisone, Placebo - Healthy
Phase 3CompletedUniversity of Texas Southwestern Medical Center172008-01-012015-08-19
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
Quetiapine fumarate (Seroquel) SR - Affective Psychosis, Bipolar, Manic Disorder
Phase 3CompletedAstraZeneca4472007-01-012009-03-25
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
Olanzapine, Paliperidone ER, Placebo - Bipolar Disorder
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.7682006-05-012015-04-15
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
Placebo, Quetiapine, Paliperidone ER - Bipolar Disorder, Mood Disorders
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.4932006-04-012014-06-20
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
Paliperidone ER - Affective Psychosis, Bipolar, Bipolar Disorder
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.3002006-04-012011-05-18
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
Paliperidone extended-release - Bipolar Disorder, Mood Disorders
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.4732006-02-012011-06-09
Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder
olanzapine, lithium, valproate - Manic or Mixed Episode Associated With Bipolar I Disorder
Phase 3CompletedEli Lilly and Company1392005-11-012010-12-28
Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients
Quetiapine Fumarate, Lithium - Mania, Bipolar Disorder
Phase 3CompletedAstraZeneca1502005-08-012010-12-09

Showing 20 of 45. Sign in to see all of them.

Narrower conditions

Bipolar Disorder (32)  ·  Affective Disorders, Psychotic (5)  ·  Psychotic Disorders (5)  ·  Depression (4)  ·  Mood Disorders (4)  ·  Schizophrenia (2)  ·  Cocaine-Related Disorders (1)  ·  Mental Disorders (1)  ·  Teratogenesis (1)

Broader conditions

Nervous System Diseases (45)  ·  Neurobehavioral Manifestations (45)  ·  Neurologic Manifestations (45)  ·  Pathological Conditions, Signs and Symptoms (45)  ·  Signs and Symptoms (45)  ·  Mental Disorders (33)  ·  Bipolar and Related Disorders (32)  ·  Mood Disorders (28)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (10)  ·  Behavior (4)  ·  Behavioral Symptoms (4)  ·  Chemically-Induced Disorders (1)  ·  Pathologic Processes (1)  ·  Substance-Related Disorders (1)

Interventions

Risperidone (7)  ·  Topiramate (5)  ·  Valproic Acid (5)  ·  10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide (4)  ·  Lithium (4)  ·  Quetiapine Fumarate (4)  ·  cariprazine (4)  ·  Olanzapine (3)  ·  Paliperidone Palmitate (3)  ·  brexpiprazole (3)  ·  Aripiprazole (2)  ·  Lithium Carbonate (2)  ·  Adrenal Cortex Hormones (1)  ·  Allopurinol (1)  ·  Carbamazepine (1)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (13)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (5)  ·  Abbott (3)  ·  Forest Laboratories (3)  ·  Novartis Pharmaceuticals (3)  ·  University of Texas Southwestern Medical Center (3)  ·  AstraZeneca (2)  ·  Eli Lilly and Company (2)  ·  AbbVie (1)  ·  Beersheva Mental Health Center (1)  ·  Biohaven Therapeutics Ltd. (1)  ·  Janssen Pharmaceutica N.V., Belgium (1)  ·  Michael Kluge (1)  ·  Novartis (1)  ·  Ortho-McNeil Neurologics, Inc. (1)

Countries

United States (26)  ·  Ukraine (7)  ·  Russia (6)  ·  Poland (5)  ·  Serbia (5)  ·  Bulgaria (4)  ·  Croatia (3)  ·  Germany (3)  ·  Romania (3)  ·  China (2)  ·  France (2)  ·  Hungary (2)  ·  India (2)  ·  Israel (2)  ·  Japan (2)

Top investigators

Elizabeth Diaz, MD (3)  ·  Matthew Leoni, M.D. (2)  ·  Alan G. Mallinger, M.D. (1)  ·  Barbara Geller, MD (1)  ·  Catherine Datto, MD (1)  ·  Clara Gu (1)  ·  E. Sherwood Brown, PH.D., M.D. (1)

Results publications

PMID 19325497, PMID 29017067, PMID 31344528, PMID 12091192, PMID 12562742, PMID 15169694, PMID 15572276, PMID 16086617, PMID 16135859, PMID 17107240, PMID 17335331, PMID 19594501, PMID 19906348, PMID 20361904, PMID 20565430, PMID 20624657, PMID 20947174, PMID 21823911, PMID 22054797, PMID 22134043, PMID 22213771, PMID 22377512, PMID 22917200, PMID 23437959, PMID 23480324, PMID 25562205, PMID 26598475, PMID 26598476, PMID 28843918, PMID 29174864, PMID 35235061

NIH funding

2017 (2), R01MH069801 (1), U01MH064846 (1), U01MH064850 (1), U01MH064868 (1), U01MH064869 (1), U01MH064887 (1), U01MH064911 (1)